The DOI matches its Crossref record; 99 of the 104 references it cites were found in a registry or an index.
Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review
Abstract
A major challenge in tuberculosis control is the diagnosis and treatment of latent tuberculosis infection. Until recently, there were no alternatives to the tuberculin skin test (TST) for diagnosing latent tuberculosis. However, an alternative has now emerged in the form of a new in-vitro test: the interferon-gamma assay. We did a systematic review to assess the performance of interferon-gamma assays in the immunodiagnosis of tuberculosis. By searching databases, contacting experts and test manufacturers, we identified 75 relevant studies. The results suggest that interferon-gamma assays that use Mycobacterium tuberculosis-specific region of difference 1 (RD1) antigens (such as early secretory antigenic target 6 and culture filtrate protein 10) may have advantages over the TST, in terms of higher specificity, better correlation with exposure to M tuberculosis, and less cross-reactivity due to BCG vaccination and non-tuberculous mycobacterial infection. However, interferon-gamma assays that use RD1 antigens in isolation may maximise specificity at the cost of sensitivity. Assays that use cocktails of RD1 antigens seem to overcome this problem, and such assays have the highest accuracy. RD1-based interferon-gamma assays can potentially identify those with latent tuberculosis who are at high risk for developing active disease, but this requires confirmation. There is inadequate evidence on the value of interferon-gamma assays in the management of immunocompromised individuals, children, patients with extrapulmonary or non-tuberculous mycobacterial disease, and populations in countries where tuberculosis is endemic. Current evidence suggests that interferon-gamma assays based on cocktails of RD1 antigens have the potential to become useful diagnostic tools. Whether this potential can be realised in practice remains to be confirmed in well designed, long-term studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because interferonc release assays (IGRAs) are not affected by BCG or nontuberculous mycobacteria other than M. marinum , M. kansasii, and M. szulgai, they are more specific than the TST [39].”
From Current diagnosis and management of peripheral tuberculous lymphadenitis. (2011) · cites this paper as [39]
Citations
Cites
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
Empirical evidence of design-related bias in studies of diagnostic tests.
Lijmer, J. G. (1999) · JAMA · doi:10.1001/jama.282.11.1061 · Cited by 1,861
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.16141 · Cited by 1,525
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.supplement_3.ats600 · Cited by 1,241
Specific immune-based diagnosis of tuberculosis
Andersen, P., Munk, M., Pollock, J., & Doherty, T. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02742-2 · Cited by 924
Huebner, R. E., Schein, M. F., & Bass, J. B. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.6.968 · Cited by 917
Specific Detection of Tuberculosis Infection: An Interferon-γ–based Assay Using New Antigens
Mori, T., Sakatani, M., Yamagishi, F., Takashima, T., Kawabe, Y., Nagao, K., Shigeto, E., Harada, N., Mitarai, S., Okada, M., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200402-179oc · Cited by 657
Ewer, K., Deeks, J., Alvarez, L., Bryant, G., Waller, S., Andersen, P., Monk, P., & Lalvani, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12950-9 · Cited by 615
Sørensen, A. L., Nagai, S., Houen, G., Andersen, P., & Andersen, A. B. (1995) · Infection and Immunity · doi:10.1128/iai.63.5.1710-1717.1995 · Cited by 586
Jasmer, R. M., Nahid, P., & Hopewell, P. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp021045 · Cited by 497
Research works printed but not linked: 1
- Ravn, 2004, The diagnostic potential of the QuantiFERON-RDl test in patients with active tuberculosis. Abstract O411, Clin Microbiol Infect, 10, 80
Cited by
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Self-citationSaag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23721 · Cited by 1,157
Menzies, D., Pai, M., & Comstock, G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00006 · Cited by 984
Self-citationElectrochemical Methods for the Analysis of Clinically Relevant Biomolecules
Labib, M., Sargent, E. H., & Kelley, S. O. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00220 · Cited by 976
Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection
Pai, M., Denkinger, C. M., Kik, S. V., Rangaka, M. X., Zwerling, A., Oxlade, O., Metcalfe, J. Z., Cattamanchi, A., Dowdy, D. W., Dheda, K., et al. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00034-13 · Cited by 886
Self-citation
Metadata
- Authors
- Pai, M., Riley, L. W., & Colford, J. M.
- Affiliations
- University of California, Berkeley (US)
- Corresponding author
- Pai, Madhukar
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2004-12
- Volume
- 4
- Issue
- 12
- Pages
- 761-776
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2008333878
- Cited by
- 913
- References
- 104
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 13 · 2023: 12 · 2022: 16 · 2021: 17 · 2020: 18 · 2019: 16 · 2018: 27 · 2017: 30 · 2016: 36 · 2015: 35 · 2014: 49 · 2013: 57 · 2012: 46
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fogarty International Center (1-D43-TW00003-15, D43TW000003)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Infectious Diseases › Diagnosis and treatment of tuberculosis
- Keywords
- interferon-gamma release assay, latent tuberculosis infection, tuberculosis diagnosis, tuberculin skin test, ESAT-6, CFP-10, diagnostic accuracy, nontuberculous mycobacteria, immunocompromised patients, children
- MeSH terms
- Antigens, Bacterial, BCG Vaccine, Cross Reactions, Humans, Immunologic Tests, Interferon-gamma, Mycobacterium tuberculosis, Sensitivity and Specificity, Tuberculin Test, Tuberculosis, Reproducibility of Results, Virus Latency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. https://app.cochat.ai/papers/10.1016/s1473-3099(04)01206-x
- The paper
- Pai, M., Riley, L. W., & Colford, J. M. (2004). Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(04)01206-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.